Literature DB >> 19945352

A prolonged protein kinase C-mediated, opioid-related antinociceptive effect of st John's Wort in mice.

Nicoletta Galeotti1, Elisa Vivoli, Anna Rita Bilia, Maria Camilla Bergonzi, Alessandro Bartolini, Carla Ghelardini.   

Abstract

UNLABELLED: The antinociceptive profile of St. John's Wort (SJW) was investigated in mice in a condition of acute thermal and chemical pain, together with the mechanism that might underlie this effect. A dried extract of SJW induced a prolonged antinociception that persisted for 120 minutes after administration. The thermal antinociception was prevented by naloxone and by the protein kinase C (PKC) activator PMA, whereas the chemical antinociception was prevented by PMA, remaining naloxone insensitive. A chloroform (CHL) and a methanol (MET) fraction, obtained to investigate the involvement of the SJW main components, hyperforin and hypericin/flavonoid, respectively, increased pain threshold with a time course comparable to the dried extract. The CHL antinociception was prevented by naloxone, whereas the MET antinociception was antagonized by PMA. Purified hyperforin and hypericin showed an antinociceptive efficacy comparable to CHL and MET, respectively. Conversely, flavonoids were devoid of any effect. The administration of yohimbine and atropine did not modify SJW, CHL and MET antinociception. These results indicate that both CHL and MET fractions mediate the SJW-induced antinociception. In particular, the presence of hypericin was fundamental to induce both thermal and chemical antinociception through the inhibition of the PKC activity, whereas hyperforin selectively produced a thermal opioid antinociception. PERSPECTIVE: This article presents evidence of a persistent thermal and chemical antinociception of SJW that is mainly mediated by PKC-inhibiting mechanisms. These findings identify important targets for a longer-acting activation of endogenous pain systems and should potentially help clinicians who seek safe, tolerable, and prolonged treatments for pain relief. Copyright 2010 American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19945352     DOI: 10.1016/j.jpain.2009.06.013

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  5 in total

1.  Phytomedicines in the Treatment of Migraine.

Authors:  Thilinie Rajapakse; William Jeptha Davenport
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

2.  Antinociceptive activity of Hypericum grandifolium Choisy in mice.

Authors:  Celia Xiomara Bonkanka; Candelaria Del Carmen Sánchez-Mateo; Rosa María Rabanal
Journal:  J Nat Med       Date:  2010-10-16       Impact factor: 2.343

3.  Reversal of NO-induced nociceptive hypersensitivity by St. John's wort and hypericin: NF-κB, CREB and STAT1 as molecular targets.

Authors:  Nicoletta Galeotti; Carla Ghelardini
Journal:  Psychopharmacology (Berl)       Date:  2012-12-20       Impact factor: 4.530

4.  Antinociceptive and Antioxidant Activities of Phytol In Vivo and In Vitro Models.

Authors:  Camila Carolina de Menezes Patrício Santos; Mirian Stiebbe Salvadori; Vanine Gomes Mota; Luciana Muratori Costa; Antonia Amanda Cardoso de Almeida; Guilherme Antônio Lopes de Oliveira; Jéssica Pereira Costa; Damião Pergentino de Sousa; Rivelilson Mendes de Freitas; Reinaldo Nóbrega de Almeida
Journal:  Neurosci J       Date:  2013-06-11

5.  Targeting the pregnane X receptor using microbial metabolite mimicry.

Authors:  Zdeněk Dvořák; Felix Kopp; Hao Li; Aneta Vrzalová; Cait M Costello; Jazmin S Kemp; Martina Štěpánková; Iveta Bartoňková; Eva Jiskrová; Karolína Poulíková; Barbora Vyhlídalová; Lars U Nordstroem; Chamini V Karunaratne; Harmit S Ranhotra; Kyu Shik Mun; Anjaparavanda P Naren; Iain A Murray; Gary H Perdew; Julius Brtko; Lucia Toporova; Arne Schön; Bret D Wallace; William G Walton; Matthew R Redinbo; Katherine Sun; Amanda Beck; Sandhya Kortagere; Michelle C Neary; Aneesh Chandran; Saraswathi Vishveshwara; Maria M Cavalluzzi; Giovanni Lentini; Julia Yue Cui; Haiwei Gu; John C March; Shirshendu Chatterjee; Adam Matson; Dennis Wright; Kyle L Flannigan; Simon A Hirota; Ryan Balfour Sartor; Sridhar Mani
Journal:  EMBO Mol Med       Date:  2020-03-10       Impact factor: 12.137

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.